J. Calop, C. Fernandez, and S. Limat, Pharmacie clinique et thérapeutique. 3 e éd, 2008.

P. Queneau and P. Grandmottet, Rapport de la mission sur la iatrogénie médicamenteuse et sa prévention, 1998.

E. Schmitt, Dictionnaire français de l'erreur médicamenteuse -Sous l'égide de la Société Française de Pharmacie Clinique, 2006.

. E_semio-medecine-interne, Sémiologie de l'hémostase. consulté le 10 octobre, 2011.

. Afssaps, Mise au point sur le bon usage des antivitamine K, 2009.

. Afssaps, Schéma commun des Autorisations de Mise sur le Marché (AMM) des spécialités AVK, 2011.

J. Ansell, J. Hirsh, and E. Hylek, Pharmacology and management of the vitamin K antagonists

. Vidal-recos, A. Traitement, D. Consulté-le-salem, P. Stein, and A. Ahmad, URL : http://www.vidalrecos.fr/pages/index.php?url=login&idfiche=1511&titre=Traitement_par_AVK. 11 Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, vol.126, pp.457-482, 2004.

. Suivi-biologique-du-traitement-par-antivitamine-k-etude-de-l-'afssaps, 14. HAS. Prise en charge des surdosages, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier, AFSSaPS. Traitement, vol.15, 2000.

P. Michel, C. Minodier, L. Thelize, and M. , Les événements indésirables graves associés aux soin dans les établissements de santé -ENEIS 2 -Sous la direction de la recherche des études de l'évaluation et des statistiques, 2009.

H. Lipczak and B. Pedersen, Bulletin de la direction de la recherche des études de l'évaluation des statistiques Incidence of adverse events in hospitals. A retrospective study of medical records, Ugeskr Laeger, vol.163, pp.5370-5378, 2001.

J. Aranaz-andres, C. Aibar-remon, and J. Vitaller-burillo, Impact and preventability of adverse events in Spanish public hospitals: results of the Spanish National Study of Adverse Events (ENEAS), International Journal for Quality in Health Care, vol.21, issue.6, pp.408-422
DOI : 10.1093/intqhc/mzp047

R. Wilson, W. Runciman, R. Gibberd, and B. Harrison, The Quality in Australian Health Care Study, Med J Aust, vol.163, pp.458-71, 1995.

R. Amalberti, C. Gremion, Y. Auroy, and P. Michel, Les systèmes de signalement des événements indésirables en médecine -Études et résultats n°584 Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance, Therapie, vol.54, pp.21-28, 1999.

D. Boucherle, C. Mortalité-iatrogène-médicamenteuse:-enquête-rétrospective-au, and . De-grenoble-en, Grenoble: Université de Pharmacie Joseph Fourier; 2005. 26. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention, Am J Med, vol.95, pp.315-343, 1993.

. Afssaps, URL: http://www.afssaps.fr/Infos-de-securite/Communiques-Points-presse/Medicaments-et-aliments-lire-lanotice-pour-eviter-les-interactions/(language )/fre-FR 28. ANSES. Aliments riches en vitamine K. consulté le 2 octobre URL: http://www.anses.fr/Documents/TNA-Fi-Vit-K.pdf. 29 Use of herbal products and potential interactions in patients with cardiovascular diseases, J Am Coll Cardiol, vol.55, pp.515-540, 2008.

S. Bourget, M. Baudrant, B. Allenet, and J. Calop, Oral anticoagulants: a literature review of herbdrug interactions or food-drug interactions, J Pharm Belg, vol.62, pp.69-75, 2007.

M. Baudrant, B. Allenet, A. Mariotte, and J. Calop, Effet d'un traitement par extraits de soja concentrés en isoflavones (Phytosoya®) sur l'efficacité d'un traitement par fluindione, pharmactuel, vol.37, pp.256-60, 2004.

A. Hajje, A. Calop, N. Bosson, J. Calop, J. Allenet et al., Quels facteurs associ??s ?? la survenue d???un ??v??nement iatrog??ne h??morragique chez les patients sous antivitamines??K???, Annales Pharmaceutiques Fran??aises, vol.68, issue.1, pp.36-43, 2010.
DOI : 10.1016/j.pharma.2009.11.003

R. Haynes, Compliance in Health Care, pp.1-15, 1979.

C. Tourette-turgis, M. Rébillon, A. Magnan, and D. Vervloet, Mettre en place une consultation d'observance aux traitements contre le VIH/Sida : de la théorie à la pratique Comment dire ed; 2002. 35. Baudrant M, Calop N, Allenet B. Chap 62. L'éducation thérapeutique du patient : contexte, concepts Compliance, therapeutic observance and therapeutic adherence: what do we speak about?, Rev Mal Respir, vol.22, pp.31-35, 2005.

P. Price, Education, psychology and ???compliance???, Diabetes/Metabolism Research and Reviews, vol.27, issue.S1, pp.101-106, 2008.
DOI : 10.1002/dmrr.851

J. Aronson, Compliance, concordance, adherence, British Journal of Clinical Pharmacology, vol.27, issue.348, pp.383-387, 2007.
DOI : 10.1097/00005650-199808000-00004

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203247

G. Treharne, A. Lyons, E. Hale, K. Douglas, G. Kitas et al., Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable Optimizing medicines management : from compliance to concordance, Rheumatology (Oxford). England; Therapeutics and Clinical Risk Management, vol.20063, issue.6, pp.1047-58, 2007.

J. Robinson, An interactional structure of medical activities during acute visits an dits implications, pp.27-59

M. Baudrant-boga, Penser autrement le comportement d'adhésion du patient au traitement médicamenteux : modélisation d'une intervention éducative ciblant le patient et ses médicaments dans le but de développer des compétences mobilisables au quotidien -Application aux patients diabétiques de type 2. Grneoble:Université Joseph Fourier, 2009.

. Bruxelles, Ecole de Santé publique, unité d'éducation pour la santé Réso; 1994. 44. Adherence to long-term therapies: evidence for action -Sous l'égide de l'Organisation Mondiale de la Santé, 2003.

K. Ingersoll and J. Cohen, The impact of medication regimen factors on adherence to chronic treatment: a review of literature, Journal of Behavioral Medicine, vol.12, issue.6, pp.213-237, 2008.
DOI : 10.1007/s10865-007-9147-y

J. George and S. Shalansky, Predictors of refill non-adherence in patients with heart failure, British Journal of Clinical Pharmacology, vol.20, issue.4, pp.488-93, 2007.
DOI : 10.1097/01.mlr.0000129496.05898.02

A. Claxton, J. Cramer, and C. Pierce, A systematic review of the associations between dose regimens and medication compliance, Clinical Therapeutics, vol.23, issue.8, pp.1296-310, 2001.
DOI : 10.1016/S0149-2918(01)80109-0

L. Lopez, D. Grimes, M. Gallo, and K. Schulz, Skin patch and vaginal ring versus combined oral contraceptives for contraception, Cochrane Database Syst Rev, p.3552, 2010.
DOI : 10.1002/14651858.cd003552.pub3

H. Marshall, W. Polonsky, L. Fisher, S. Guzman, L. Villa-caballero et al., The Health belief model and personal health behavior San fransisco: Society for Public Health Education; 1974. 50 Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem, Diabetes Care. United States, vol.2005, pp.2543-2549

J. Fuertes, A. Mislowack, and J. Bennett, The physician???patient working alliance, Patient Education and Counseling, vol.66, issue.1, pp.29-36, 2007.
DOI : 10.1016/j.pec.2006.09.013

C. Koning, A. Maillé, and I. Stevens, Patients' Opinions on Respiratory Care: Do Doctors Fulfill Their Needs?, Journal of Asthma, vol.8, issue.5, pp.355-63, 1995.
DOI : 10.1300/J026v03n01_04

. Afssaps, Annales du contrôle national de qualité des analyses de biologie médicale, 2003.

G. Palareti, N. Leali, and S. Coccheri, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy, Lancet. England, pp.423-431, 1996.

E. Chiquette, M. Amato, and H. Bussey, Comparison of an Anticoagulation Clinic With Usual Medical Care, Archives of Internal Medicine, vol.158, issue.15, pp.1641-1648, 1998.
DOI : 10.1001/archinte.158.15.1641

S. Leger, B. Allenet, and O. Pichot, Impact of an education program on patient behaviour favoring prevention of drug-related adverse events: a pilot study in patients receiving oral anticoagulants for thromboembolic venous disease France; 2004:152-8. 58. HAS. Éducation thérapeutique du patient -Comment élaborer un prgramme spécifique d'une maladie chronique, J Mal Vasc, 2007.

M. Petersen, Y. Wang, M. Van-der-laan, D. Guzman, E. Riley et al., Pillbox Organizers are Associated with Improved Adherence to HIV Antiretroviral Therapy and Viral Suppression: a Marginal Structural Model Analysis, Clinical Infectious Diseases, vol.45, issue.7, pp.908-923
DOI : 10.1086/521250

J. Lee, K. Grace, and A. Taylor, Effect of a Pharmacy Care Program on Medication Adherence and Persistence, Blood Pressure, and Low-Density Lipoprotein Cholesterol, JAMA, vol.296, issue.21, pp.2563-71, 2006.
DOI : 10.1001/jama.296.21.joc60162

C. Maier, . Md, E. Schuster, A. Luger, R. Eher et al., Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications, Diabet Med AIDS Read, vol.2310, issue.62, pp.40-5177, 2000.

T. Hayes, K. Cobbinah, and T. Dishongh, A Study of Medication-Taking and Unobtrusive, Intelligent Reminding, Telemedicine and e-Health, vol.15, issue.8, pp.770-776, 2009.
DOI : 10.1089/tmj.2009.0033

L. Poller, C. Shiach, and P. Maccallum, Multicentre randomised study of computeris ed anticoagulant dosage. European Concerted Action on Anticoagulation, Lancet. England, pp.1505-1514, 1998.

L. Poller, M. Keown, and S. Ibrahim, A multicentre randomised clinical endpoint study of parma 5 computer-assisted oral anticoagulant dosage, British Journal of Haematology, vol.90, issue.suppl, pp.274-83
DOI : 10.1111/j.1365-2141.2008.07337.x

L. Poller, M. Keown, and S. Ibrahim, An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage, Journal of Thrombosis and Haemostasis, vol.69, issue.6, pp.935-978
DOI : 10.1056/NEJM199507063330103

S. Jowett, S. Bryan, and L. Poller, The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study, Journal of Thrombosis and Haemostasis, vol.11, issue.Suppl, pp.1482-90
DOI : 10.1111/j.1538-7836.2009.03508.x

C. Stevens and A. Fry-smith, Commission nationale d'evaluation des dispositifs medicaux et des technologies de santé -Avis de la commssion du 12 juillet 2011. 70. HAS. Evaluation de l'autosurveillance de l'INR chez les patients zdultes traités par les antivitamines K. Octobre Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling, Coaguchek XS System -Manuel d'utilisation. consulté le 2 octobre 201pdf. 69. HAS, p.66, 2008.

. Afssaps, Points d'information sur les dossiers discutés en commission d'AMM -Séance du jeudi 24 mars URL: http://www.afssaps.fr/Infos-de-securite/Communiques-Points- presse/Points-d-information-sur-les-dossiers-discutes-en-commission-d-AMM-Seance-du-jeudi-24- mars-2011-Communique, pp.fre-FR, 2011.

J. Garcia-alamino, A. Ward, and P. Alonso-coello, Self-monitoring and self-management of oral anticoagulation Meta-analysis: effect of patient self-testing and selfmanagement of long-term anticoagulation on major clinical outcomes, 76. Ward AM HC, Perera R. What are the basic self-monitoring components for cardiovascular risk management, pp.472-82105, 2010.

C. Heneghan, P. Alonso-coello, J. Garcia-alamino, R. Perera, E. Meats et al., Selfmonitoring of oral anticoagulation: a systematic review and meta-analysis, Lancet. England, vol.2006, pp.404-415

T. Christensen, S. Johnsen, V. Hjortdal, and J. Hasenkam, Self-management of oral anticoagulant therapy: A systematic review and meta-analysis, International Journal of Cardiology, vol.118, issue.1, pp.54-61, 2007.
DOI : 10.1016/j.ijcard.2006.06.018

C. Laurence, J. Moss, N. Briggs, J. Beilby, and P. Group, The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial, BMC Health Services Research, vol.60, issue.1, p.165, 2010.
DOI : 10.3399/bjgp10X483508

D. Matchar, A. Jacobson, and R. Dolor, Effect of Home Testing of International Normalized Ratio on Clinical Events, New England Journal of Medicine, vol.363, issue.17, pp.1608-1628, 2010.
DOI : 10.1056/NEJMoa1002617

M. Bauman, K. Black, and M. Bauman, EMPoWarMENT: Edmonton Pediatric Warfarin Self-Management Pilot Study in Children with Primarily Cardiac Disease, Thrombosis Research, vol.126, issue.2, pp.110-115, 2010.
DOI : 10.1016/j.thromres.2010.05.024

F. Ryan, O. Shea, S. Byrne, and S. , The ???carry-over??? effects of patient self-testing: Positive effects on usual care management by an anticoagulation management service, Thrombosis Research, vol.126, issue.5, p.2010
DOI : 10.1016/j.thromres.2010.08.001

G. Pernod, J. Labarere, and J. Yver, EDUC???AVK: Reduction of Oral Anticoagulant-related Adverse Events After Patient Education: A Prospective Multicenter Open Randomized Study, Journal of General Internal Medicine, vol.40, issue.9, pp.1441-1447, 2008.
DOI : 10.1007/s11606-008-0690-1

URL : https://hal.archives-ouvertes.fr/hal-00291806

C. Dauphin, B. Legault, and P. Jaffeux, Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients Does point-of-care testing lead to the same or better adherence to medication? A randomised controlled trial: the PoCT in General Practice Trial, Arch Cardiovasc Dis. Netherlands; Med J Aust, vol.2008191, pp.753-61487, 2009.

L. Lalonde, J. Martineau, and N. Blais, Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial, American Heart Journal, vol.156, issue.1, pp.148-54
DOI : 10.1016/j.ahj.2008.02.009

A. Gadisseur, A. Kaptein, W. Breukink-engbers, F. Van-der-meer, and F. Rosendaal, Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life, Journal of Thrombosis and Haemostasis, vol.25, issue.4, pp.584-91
DOI : 10.1037//0022-006X.70.3.459

T. Khan, F. Kamali, P. Kesteven, P. Avery, and H. Wynne, The value of education and selfmonitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation, Br J Haematol. England, vol.2004, pp.557-64

J. Ansell, A. Jacobson, J. Levy, H. Voller, and J. Hasenkam, Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation, International Journal of Cardiology, vol.99, issue.1, pp.37-45, 2005.
DOI : 10.1016/j.ijcard.2003.11.008

C. Gardiner, I. Longair, and M. Pescott, Self-monitoring of oral anticoagulation: does it work outside trial conditions?, Journal of Clinical Pathology, vol.62, issue.2, pp.168-71
DOI : 10.1136/jcp.2008.059634

V. Wilt, J. Gums, O. Ahmed, and L. Moore, Outcome analysis of a pharmacist-managed anticoagulation service, Pharmacotherapy, vol.15, pp.732-741, 1995.

S. John, A. Laurence, C. Bubner, and T. , Optimal oral anticoagulant therapy in patients with mechanical heart valves Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review, N Engl J Med Fam Pract, vol.33327, pp.11-717, 1995.

R. Beyth, L. Quinn, and C. Landefeld, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med. United States, pp.91-100, 1998.

T. Bubner, C. Laurence, and A. Gialamas, Effectiveness of point-of-care testing for therapeutic control of chronic conditions: Results from the PoCT in General Practice Trial, Med J Aust, vol.190, pp.624-630, 2009.

N. Kagansky, H. Knobler, E. Rimon, Z. Ozer, S. Levy et al., Safety of anticoagulation therapy in wellinformed older patients Arch Intern Med United States Does point-of-care testing lead to the same or better adherence to medication? A randomised controlled trial: the PoCT in General Practice Trial, Med J Aust, vol.2004, pp.2044-50487, 2009.

T. Hua, S. Vormfelde, A. Abed, and M. , Practice nursed-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a cluster-randomized controlled trial, BMC Family Practice, vol.29, issue.1, p.17, 2011.
DOI : 10.1002/9780470510445

P. Sawicki, A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self- Management of Oral Anticoagulation, JAMA. United States, vol.1999, pp.145-50

J. Lafata, S. Martin, S. Kaatz, and R. Ward, The cost-effectiveness of different management strategies for patients on chronic warfarin therapy, Journal of General Internal Medicine, vol.46, issue.1, pp.31-38
DOI : 10.1046/j.1525-1497.2000.01239.x

M. Gold, J. Siegel, L. Russell, and M. Weinstein, Cost-effectiveness in health and medicine, J Ment Health Policy Econ, vol.2, issue.2, pp.91-92, 1996.

P. Taboulet and J. Feugeas, Biologie délocalisée ou centralisée ? Introduction au concept de biotest-dépendance, 103. HAS. Activités de biologie médicale et certification des établissements de santé. Mars, pp.21-28, 2006.

M. Kong, T. Lim, H. Ng, Y. Chan, and L. Lee, Feasibility, cost-effectiveness and patients??? acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic, Annals of Hematology, vol.126, issue.3 Suppl, pp.905-915, 2008.
DOI : 10.1007/s00277-008-0530-8

L. Cohet, Intérêt de l'INR capillaire dans l'optimisation de la prise en charge des surdosages en AVK dans le service des urgences médicales du groupement hospitalier E. Herriot (Hospice civils de Lyon), 2010.

. Afssaps and . De-mise-sur-le-marché-du-xarelto, Surveillance-des-medicaments/Medicaments-faisant-l-objet-d- une-surveillance-renforcee-des-le-debut-de-leur-commercialisation/Medicaments-et-classes-de- medicaments-faisant-l-objet-d-une-surveillance-renforcee-depuis-le-debut-de-la- commercialisation/XARELTO-R 107. AFSSaPS Autorisation de mise sur le marché du Pradaxa. consulté le 28 septembre 2011: URL: http://www.afssaps.fr/Activites/Surveillance-des-medicaments/Medicaments-faisant-l-objet-d- une-surveillance-renforcee-des-le-debut-de-leur-commercialisation/Medicaments-et-classes-demedicaments-faisant-l-objet-d-une-surveillance-renforcee-depuis-le-debut-de-lacommercialisation/PRADAXA-R/(language )/fre-FR 108. AFFSaPS. Points d'information sur les dossiers discutés en commission d'AMM Séance du jeudi 28 avril 2011 109, Medscape education. Coagulation Simplified : Newer Oral Anticoagulant Agents. Consulté le 4 octobre 2011:URL: http://www.medscape.org/viewarticle/725813_9. 110. Gross PL, Weitz JI. New antithrombotic drugs, pp.139-185, 2011.

R. Friedman, O. Dahl, and N. Rosencher, Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials, Thrombosis Research, vol.126, issue.3, pp.175-82, 2010.
DOI : 10.1016/j.thromres.2010.03.021

G. Landman and R. Gans, Oral rivaroxaban for symptomatic venous thromboembolism

M. Patel, K. Mahaffey, and J. Garg, Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

S. Connolly, M. Ezekowitz, and S. Yusuf, Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

C. Granger, J. Alexander, and J. Mcmurray, Apixaban versus Warfarin in Patients with Atrial Fibrillation, HAS. Avis de la commission de transparence sur le Xarelto -CT 6017. 21 janvier 2009. 120. HAS. Avis de la commission de transparence sur le Pradaxa -CT 5528. 16 juillet, pp.981-92, 2008.
DOI : 10.1056/NEJMoa1107039

J. Despres, Etude de sécabilité comparée de la fluindione et de la warfarine. Paris: Faculté de médecine Paris Descartes, 2009.

H. Takahashi, G. Wilkinson, and E. Nutescu, Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans, Pharmacogenetics and Genomics, vol.16, issue.2, pp.101-111, 2006.
DOI : 10.1097/01.fpc.0000184955.08453.a8

V. Siguret, I. Gouin, J. Golmard, S. Geoffroy, J. Andreux et al., Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie ?? l?????quilibre pour des patients ??g??s trait??s par warfarine, La Revue de M??decine Interne, vol.25, issue.4, pp.271-275, 2004.
DOI : 10.1016/j.revmed.2003.11.006

S. Rost, A. Fregin, and V. Ivaskevicius, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, vol.427, issue.6974, pp.537-578, 2004.
DOI : 10.1038/nature02214